Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

Healthcare costs and outcomes of invasive Group A Streptococcus (iGAS) disease in Ontario, Canada: A population-based cohort study

EF 2025-26

Résumé
Group A Streptococcus (GAS) is a common and contagious bacterium. While many infections are mild, some become severe and life-threatening. Serious cases, such as toxic shock syndrome and necrotizing fasciitis, are known as invasive GAS (iGAS) disease. In Ontario, the number of people with iGAS has been rising for decades. It reached about 1,960 cases in 2023–2024, the highest ever recorded. Numbers fell slightly in 2024–2025 but are still higher than before the COVID-19 pandemic. Most people with iGAS need hospital care, and about 11% of people with iGAS in Ontario die. Survivors can develop long-term problems, such as rheumatic heart disease, which can cause more deaths later. The financial impact of iGAS is also significant. While no one has studied the health and economic impact of iGAS in Canada, studies from other high-income countries show that one episode of acute iGAS illness can cost more than US $34,000, including costs of care and income losses. My thesis will study the impact of iGAS on health and healthcare costs in Ontario. I will use Ontario population-based health data from 2000 to 2025 to identify people who had iGAS to learn about hospitalizations, complications, long-term effects, and deaths. I will also calculate how much their care cost the health system by considering all publicly funded health services. By looking at differences by age, sex, and socioeconomic status, I will examine which groups are most affected and where inequities exist. This will be the first study to describe the health and economic burden of iGAS in Ontario. The findings will help guide future decisions on how to prevent and manage iGAS disease and how to reduce disparities to improve outcomes.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
573162
Name
Pinkevych Serhii
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Healthcare costs and outcomes of invasive Group A Streptococcus (iGAS) disease in Ontario, Canada: A population-based cohort study
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Equity And Health Disparities; Health Administrative Data (Ices); Health And Economic Burden; Hospitalization And Mortality; Invasive Group A Streptococcus (Igas); Phase-Of-Care Costing; Population-Based Cohort; Rheumatic Heart Disease (Rhd); Streptococcus Pyogenes; Vaccine Policy And Prevention
Abstract
Group A Streptococcus (GAS) is a common and contagious bacterium. While many infections are mild, some become severe and life-threatening. Serious cases, such as toxic shock syndrome and necrotizing fasciitis, are known as invasive GAS (iGAS) disease. In Ontario, the number of people with iGAS has been rising for decades. It reached about 1,960 cases in 2023–2024, the highest ever recorded. Numbers fell slightly in 2024–2025 but are still higher than before the COVID-19 pandemic. Most people with iGAS need hospital care, and about 11% of people with iGAS in Ontario die. Survivors can develop long-term problems, such as rheumatic heart disease, which can cause more deaths later. The financial impact of iGAS is also significant. While no one has studied the health and economic impact of iGAS in Canada, studies from other high-income countries show that one episode of acute iGAS illness can cost more than US $34,000, including costs of care and income losses. My thesis will study the impact of iGAS on health and healthcare costs in Ontario. I will use Ontario population-based health data from 2000 to 2025 to identify people who had iGAS to learn about hospitalizations, complications, long-term effects, and deaths. I will also calculate how much their care cost the health system by considering all publicly funded health services. By looking at differences by age, sex, and socioeconomic status, I will examine which groups are most affected and where inequities exist. This will be the first study to describe the health and economic burden of iGAS in Ontario. The findings will help guide future decisions on how to prevent and manage iGAS disease and how to reduce disparities to improve outcomes.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pinkevych, Serhii
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~